NFKB1 and Duchenne muscular dystrophy: Other anti-inflammatory compounds of increasing interest for DMD are edasalonexent (formerly CAT-1004, now being tested in a Phase II trial), NCT02439216 [96], and CAT-1041, two inhibitors of the IκB kinase (IKK)/NF-κB complex.